Detecting early kidney allograft fibrosis with multi-b-value spectral diffusion MRI
Kidney allograft fibrosis is a manifestation of chronic kidney disease (CKD) and predicts functional decline, and eventual allograft failure. This study evaluates whether spectral diffusion magnetic resonance imaging (MRI) detects early development and mild/moderate fibrosis in kidney allografts. In a prospective two-center study of kidney allografts, pathologic interstitial fibrosis and tubular atrophy (IFTA) was scored and eGFR was calculated from serum creatinine. Multi-b-value diffusion-weighted imaging (DWI) ([Formula: see text]]) was post-processed with spectral diffusion, intravoxel incoherent motion (IVIM), and apparent diffusion coefficient (ADC). Relationships between imaging parameters and biological processes were measured by Mann-Whitney U-test and Spearman's rank; diagnostic ability was measured by five-fold cross-validation univariate and multi-variate logistic regression. Quality control analyses included volunteer MRI (n = 4) and inter-observer analysis (n = 19). 99 patients were included (50 ± 13yrs, 64 M/35F, 39 IFTA = 0, 22 IFTA = 2, 20 IFTA = 4, 18 IFTA = 6, 46 eGFR ≤ 45mL/min/1.73m<sup>2</sup>, mean eGFR = 47.5 ± 21.3mL/min/1.73m<sup>2</sup>). Spectral diffusion detected fibrosis ([Formula: see text]) in patients with normal/stable [Formula: see text] [[Formula: see text]]. Spectral diffusion detected mild/moderate fibrosis (IFTA=2-4) [[Formula: see text]], as did ADC [[Formula: see text]]. eGFR, time-from-transplant, and allograft size could not. Interobserver correlation was ≥ 0.50 in 24/40 diffusion parameters. Spectral diffusion MRI showed detection of mild/moderate fibrosis and fibrosis before decline in function. It is a promising method to detect early development of fibrosis and CKD before progression.
Authors
- Octavia Bane (ORCID: https://orcid.org/0000-0003-1315-5848)
- Mira Liu (ORCID: https://orcid.org/0000-0002-8729-9302)
- Thangamani Muthukumar (ORCID: https://orcid.org/0000-0002-0294-6209)
- Jonathan P. Dyke (ORCID: https://orcid.org/0000-0001-7170-488X)
- Samira Farouk (ORCID: https://orcid.org/0000-0001-5598-5925)
- Thomas Gladytz (ORCID: https://orcid.org/0000-0003-1072-0098)
- Sai Swetha Pavuluri
- Isaac E. Stillman (ORCID: https://orcid.org/0000-0002-4224-5060)
- Surya V. Seshan (ORCID: https://orcid.org/0000-0003-4384-0694)
- Jonas Jasse (ORCID: https://orcid.org/0009-0007-5744-7830)
- Sara Lewis (ORCID: https://orcid.org/0000-0002-4713-6453)
- Bachir A. Taouli (ORCID: https://orcid.org/0000-0001-6409-1333)
- Ian Bolger
- Tanner Crews
- Sergio Calle
- Steven Salvatore
- Ananda L. Kimm-Drapeau (ORCID: https://orcid.org/0009-0006-6254-1840)
Institutions
- Citigroup (US)
- Max Delbrück Center (DE)
- Cornell University (US)
- Düsseldorf University Hospital (DE)
- Mount Sinai Hospital (US)
- Weill Cornell Medicine (US)
- Heinrich Heine University Düsseldorf (DE)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1038/s41598-025-24701-5
- Primary Topic
- MRI in cancer diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases